Dr. Robert Green has been named as Chair of the Wamberg Genomic Advisors/Cancer Guardian Advisory Board.
Dr. Robert Green
Robert C. Green, MD, MPH, a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School, has been named as Chair of Wamberg Genomic Advisors’ Advisory Board.
“Our organization is committed to providing access to clinical grade genetic testing, personalized support and advanced science to patients worldwide. We are thrilled to have Dr. Green to help lead and advance our efforts.
We believe that the addition of Dr. Green will significantly advance the global democratization of access to the best navigation, technology and guidance for enhancing prevention and survival.
Our focused target for the immediate future is cancer.”
— Tom Wamberg, CEO, Wamberg Genomic Advisors
“We are excited to work with Dr. Green. His knowledge and credibility in the field of genetics and translational medicine make us stronger as we endeavor to improve public health.”
— Dr. Phil Smalley, Chief Medical Director, Wamberg Genomic Advisors